CERE Cerevel Therapeutics Holdings Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CERE

Price (delayed)

$42.55

Market cap

$7.73B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.67

Enterprise value

$7.79B

Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry ...

Highlights
The equity has surged by 147% since the previous quarter and by 29% year-on-year
The quick ratio has increased by 25% since the previous quarter but it has declined by 13% year-on-year
The company's net income fell by 23% YoY and by 10% QoQ
The EPS has contracted by 15% YoY and by 7% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.cerevel.com
Peers: ADM SANW DOW DD

Key stats

What are the main financial stats of CERE
Market
Shares outstanding
181.58M
Market cap
$7.73B
Enterprise value
$7.79B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
11.39
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$421.77M
EBITDA
-$416.15M
Free cash flow
-$346.11M
Per share
EPS
-$2.67
Free cash flow per share
-$2.14
Book value per share
$3.74
Revenue per share
$0
TBVPS
$7.67
Balance sheet
Total assets
$1.24B
Total liabilities
$569.55M
Debt
$480.78M
Equity
$673.75M
Working capital
$914.76M
Liquidity
Debt to equity
0.71
Current ratio
10.92
Quick ratio
10.77
Net debt/EBITDA
-0.15
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-44.5%
Return on equity
-100.1%
Return on invested capital
-37%
Return on capital employed
-36.6%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CERE stock price

How has the Cerevel Therapeutics Holdings stock price performed over time
Intraday
-0.09%
1 week
0.19%
1 month
0.52%
1 year
33.3%
YTD
0.35%
QTD
0.66%

Financial performance

How have Cerevel Therapeutics Holdings's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$447.27M
Net income
-$432.84M
Gross margin
N/A
Net margin
N/A
The company's net income fell by 23% YoY and by 10% QoQ
The operating income has contracted by 22% YoY and by 8% from the previous quarter

Growth

What is Cerevel Therapeutics Holdings's growth rate over time

Valuation

What is Cerevel Therapeutics Holdings stock price valuation
P/E
N/A
P/B
11.39
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has contracted by 15% YoY and by 7% from the previous quarter
The equity has surged by 147% since the previous quarter and by 29% year-on-year
The stock's price to book (P/B) is 3.5% less than its last 4 quarters average of 11.8

Efficiency

How efficient is Cerevel Therapeutics Holdings business performance
The ROE has contracted by 49% YoY
CERE's return on invested capital is down by 8% since the previous quarter but it is up by 7% year-on-year
CERE's return on assets is down by 5% year-on-year and by 3.7% since the previous quarter

Dividends

What is CERE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CERE.

Financial health

How did Cerevel Therapeutics Holdings financials performed over time
The company's total assets is 118% higher than its total liabilities
The company's total assets has surged by 51% QoQ and by 22% YoY
The quick ratio has increased by 25% since the previous quarter but it has declined by 13% year-on-year
The debt is 29% smaller than the equity
The equity has surged by 147% since the previous quarter and by 29% year-on-year
The debt to equity has plunged by 59% from the previous quarter and by 13% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.